Literature DB >> 26855480

Combined Pharmacotherapy and Cognitive-Behavioral Therapy for Anxiety Disorders: Medication Effects, Glucocorticoids, and Attenuated Treatment Outcomes.

Michael W Otto1, R Kathryn McHugh1, Kathleen M Kantak1.   

Abstract

Despite the success of both pharmacologic and cognitive-behavioral interventions for the treatment of anxiety disorders, the combination of these modalities in adults has not resulted in substantial improvements in outcome relative to either strategy alone, raising questions about whether there are interfering effects that attenuate the magnitude of combination treatment benefits. In this article, we introduce an accounting of potential interference effects that expands upon arguments asserting the necessity of arousal for successful fear exposure. Specifically, recent advances in the study of the effects of cortisol on memory--suggesting that glucocorticoids are crucial to the learning of emotional material--have led us to posit that the attenuation of glucocorticoid activity by anxiolytic medications may interfere with extinction learning in exposure-based therapies. Implications for the efficacy of combination treatments for the anxiety disorders are discussed.

Entities:  

Keywords:  Anxiety Disorders; Cognitive-Behavioral Therapy; Combination Therapy; Extinction; Glucocorticoids; NMDA

Year:  2010        PMID: 26855480      PMCID: PMC4743901          DOI: 10.1111/j.1468-2850.2010.01198.x

Source DB:  PubMed          Journal:  Clin Psychol (New York)        ISSN: 0969-5893


  108 in total

1.  Microinjections of the dopamine D2 receptor antagonist sulpiride into the medial prefrontal cortex attenuate glucocorticoid-induced impairment of long-term memory retrieval in rats.

Authors:  Roghayeh Pakdel; Ali Rashidy-Pour
Journal:  Neurobiol Learn Mem       Date:  2006-11-22       Impact factor: 2.877

2.  The pattern of subjective anxiety during in-session exposures over the course of cognitive-behavioral therapy for clients with social anxiety disorder.

Authors:  Sarah A Hayes; Debra A Hope; Richard G Heimberg
Journal:  Behav Ther       Date:  2008-02-06

3.  Group cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series.

Authors:  M W Otto; M H Pollack; S J Penava; B G Zucker
Journal:  Behav Res Ther       Date:  1999-08

4.  Adrenoceptor mechanisms underlying imipramine-induced memory deficits in rats.

Authors:  Mohammad Reza Zarrindast; Maryam Ghiasvand; Houman Homayoun; Parvin Rostami; Bijan Shafaghi; Simin Khavandgar
Journal:  J Psychopharmacol       Date:  2003-03       Impact factor: 4.153

5.  Glucocorticoids reduce phobic fear in humans.

Authors:  Leila M Soravia; Markus Heinrichs; Amanda Aerni; Caroline Maroni; Gustav Schelling; Ulrike Ehlert; Benno Roozendaal; Dominique J-F de Quervain
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

6.  Midazolam in the reduction of surgical stress: a randomized clinical trial.

Authors:  Waseem Jerjes; Walid K Jerjes; Brian Swinson; Samintharaj Kumar; Rachel Leeson; Peter J Wood; Meir Kattan; Colin Hopper
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2005-11

7.  Effects of some new antidepressant drugs on the glucocorticoid receptor-mediated gene transcription in fibroblast cells.

Authors:  Matylda Augustyn; Magdalena Otczyk; Bogusława Budziszewska; Grzegorz Jagła; Wojciech Nowak; Agnieszka Basta-Kaim; Lucylla Jaworska-Feil; Marta Kubera; Magdalena Tetich; Monika Leśkiewicz; Władysław Lasoń
Journal:  Pharmacol Rep       Date:  2005 Nov-Dec       Impact factor: 3.024

8.  Salivary cortisol and short and long-term memory for emotional faces in healthy young women.

Authors:  Peter Putman; Jack Van Honk; Roy P C Kessels; Martijn Mulder; Hans P F Koppeschaar
Journal:  Psychoneuroendocrinology       Date:  2004-08       Impact factor: 4.905

9.  Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia.

Authors:  Jonathan R T Davidson; Edna B Foa; Jonathan D Huppert; Francis J Keefe; Martin E Franklin; Jill S Compton; Ning Zhao; Kathryn M Connor; Thomas R Lynch; Kishore M Gadde
Journal:  Arch Gen Psychiatry       Date:  2004-10

Review 10.  Combined psychotherapy plus benzodiazepines for panic disorder.

Authors:  Norio Watanabe; Rachel Churchill; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21
View more
  19 in total

Review 1.  Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.

Authors:  Michael W Otto; M Alexandra Kredlow; Jasper A J Smits; Stefan G Hofmann; David F Tolin; Rianne A de Kleine; Agnes van Minnen; A Eden Evins; Mark H Pollack
Journal:  Biol Psychiatry       Date:  2015-09-25       Impact factor: 13.382

2.  A placebo-controlled randomized trial of D-cycloserine augmentation of cue exposure therapy for smoking cessation.

Authors:  Michael W Otto; Gladys N Pachas; Corinne Cather; Susanne S Hoeppner; Samantha J Moshier; Bridget A Hearon; Heather Burrell Ward; Alexandra B Laffer; Jasper A J Smits; A Eden Evins
Journal:  Cogn Behav Ther       Date:  2018-08-16

3.  Guided Self-Help Works: Randomized Waitlist Controlled Trial of Pacifica, a Mobile App Integrating Cognitive Behavioral Therapy and Mindfulness for Stress, Anxiety, and Depression.

Authors:  Christine Moberg; Andrea Niles; Dale Beermann
Journal:  J Med Internet Res       Date:  2019-06-08       Impact factor: 5.428

Review 4.  Pharmacological enhancement of fear reduction: preclinical models.

Authors:  Bronwyn M Graham; Julia M Langton; Rick Richardson
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 5.  Memory creation and modification: Enhancing the treatment of psychological disorders.

Authors:  M Alexandra Kredlow; Howard Eichenbaum; Michael W Otto
Journal:  Am Psychol       Date:  2018-03-01

Review 6.  Cognitive enhancers for anxiety disorders.

Authors:  Stefan G Hofmann; Jasper A J Smits; Anu Asnaani; Cassidy A Gutner; Michael W Otto
Journal:  Pharmacol Biochem Behav       Date:  2010-12-04       Impact factor: 3.533

Review 7.  Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Authors:  N Singewald; C Schmuckermair; N Whittle; A Holmes; K J Ressler
Journal:  Pharmacol Ther       Date:  2014-12-27       Impact factor: 12.310

8.  Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial.

Authors:  Robert J DeRubeis; John Zajecka; Richard C Shelton; Jay D Amsterdam; Jan Fawcett; Colin Xu; Paula R Young; Robert Gallop; Steven D Hollon
Journal:  JAMA Psychiatry       Date:  2020-03-01       Impact factor: 21.596

9.  D-cycloserine deters reacquisition of cocaine self-administration by augmenting extinction learning.

Authors:  Bríd A Nic Dhonnchadha; Jonathan J Szalay; Cindy Achat-Mendes; Donna M Platt; Michael W Otto; Roger D Spealman; Kathleen M Kantak
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 10.  Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review.

Authors:  R Kathryn McHugh; Sarah W Whitton; Andrew D Peckham; Jeffrey A Welge; Michael W Otto
Journal:  J Clin Psychiatry       Date:  2013-06       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.